Epidemiology of HIV drug resistance in low-and middle-income countries and WHO global strategy to monitor its emergence
S Bertagnolio, MR Jordan, A Giron… - Current Opinion in HIV …, 2022 - journals.lww.com
Epidemiology of HIV drug resistance in low- and middle-incom... : Current Opinion in HIV and
AIDS Epidemiology of HIV drug resistance in low- and middle-income countries and WHO …
AIDS Epidemiology of HIV drug resistance in low- and middle-income countries and WHO …
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study
B Schramm, E Temfack, D Descamps, S Nicholas… - The Lancet …, 2022 - thelancet.com
Background Many countries are now replacing non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) with a regimen containing …
inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) with a regimen containing …
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
UM Parikh, JW Mellors - Current Opinion in HIV and AIDS, 2022 - journals.lww.com
PrEP is highly effective in preventing HIV infection. Although HIV drug resistance from PrEP
use could impact future options in individuals who seroconvert on PrEP, the current risk is …
use could impact future options in individuals who seroconvert on PrEP, the current risk is …
[图书][B] Improving antenatal iron-containing supplementation indicators: a report on key informant interviews, an online survey and DHS data analyses
World Health Organization… - 2020 - books.google.com
Page 1 IMPROVING ANTENATAL IRON-CONTAINING SUPPLEMENTATION INDICATORS
REPORT OF KEY INFORMANT INTERVIEWS, ONLINE SURVEY, AND DHS DATA …
REPORT OF KEY INFORMANT INTERVIEWS, ONLINE SURVEY, AND DHS DATA …
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA) …
NI Paton, J Musaazi, C Kityo, S Walimbwa, A Hoppe… - The Lancet …, 2022 - thelancet.com
Background WHO guidelines recommend dolutegravir plus two nucleoside reverse
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …
Brief report: virologic impact of the dolutegravir transition: prospective results from the Multinational African Cohort Study
E Allahna, S Neha, K Hannah, M Jonah… - JAIDS Journal of …, 2022 - journals.lww.com
Background: The real-world impact on viral suppression of switching from non–dolutegravir-
based therapy to tenofovir/lamivudine/dolutegravir (TLD) is not thoroughly characterized in …
based therapy to tenofovir/lamivudine/dolutegravir (TLD) is not thoroughly characterized in …
Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial
Background Dolutegravir concentrations are reduced by efavirenz induction effect
necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction …
necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction …
Roadmap for achieving universal antiretroviral treatment
S Sokhela, S Lalla-Edward, MJ Siedner… - Annual review of …, 2023 - annualreviews.org
Modern antiretroviral therapy safely, potently, and durably suppresses human
immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired …
immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired …
[HTML][HTML] Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in …
J Fokam, AD Nka, FYM Dzukam, JE Gabisa, Y Bouba… - Medicine, 2023 - journals.lww.com
This study aimed to compare viral suppression (VS) between children, adolescents, and
adults in the frame of transition to dolutegravir (DTG)-based antiretroviral therapy (ART) in …
adults in the frame of transition to dolutegravir (DTG)-based antiretroviral therapy (ART) in …
Advancing HIV drug resistance technologies and strategies: insights from South Africa's experience and future directions for resource-limited settings
Monitoring of HIV drug resistance (HIVDR) remains critical for ensuring countries attain and
sustain the global goals for ending HIV as a public health threat by 2030. On an individual …
sustain the global goals for ending HIV as a public health threat by 2030. On an individual …